Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions

References

• The Centers for Disease Control and Prevention. Today’s heroin epidemic [Internet]. Atlanta (GA): The Centers for Disease Control and Prevention; 2015 [ accessed 2015 Jul; cited 2017 Mar 26] https://www.cdc.gov/vitalsigns/pdf/2015-07-vitalsigns.pdf
   Google Scholar
• Trust for America’s Health. Reducing teen substance misuse: What really works [Internet]. Washington (DC): Trust for America’s Health; 2015 [ accessed 2015; cited 2017 Mar 26]. http://healthyamericans.org/assets/files/TFAH-2015-TeenSubstAbuse%20FINAL.pdf
   Google Scholar
• Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry. 2003;160(6):1041–52. doi:10.1176/appi.ajp.160.6.1041.
   PubMed Web of Science ®Google Scholar
• Ryan SA, Gonzalez PK, Patrick SW, Quigley J, Siqueira L, Walker LR. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3).
   Web of Science ®Google Scholar
• Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Linters N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;(5):CD011117.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Moore SK, Borodovsky JT, Solhkhah R, Badger GJ, Semino S, Jarrett K, Condon KD, Rossettie K, Vincent P, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016;111(8):1406–15. doi:10.1111/add.13363.
   PubMed Web of Science ®Google Scholar
• Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 2010;105(9):1616–24. doi:10.1111/add.2010.105.issue-9.
   PubMed Web of Science ®Google Scholar
• Moore SK, Guarino H, Marsch LA. “This is not who I want to be:” experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment. Subset Use Misuse. 2014;49(3):303–14. doi:10.3109/10826084.2013.832328.
   PubMed Web of Science ®Google Scholar
• Hoofer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. J Subset Abuse Treat. 2002;23(3):231–37. doi:10.1016/S0740-5472(02)00250-7.
   PubMed Web of Science ®Google Scholar
• British Columbia Centre on Substance Use. A guideline for the clinical management of opioid use disorder. Vancouver (BC): British Columbia Centre on Substance Use; 2017. [ accessed 2017 Feb; cited 2017 Mar 13]. http://www.bccsu.ca/wp-content/uploads/2017/02/BC-OUD-Guidelines_FINAL.pdf.
   Google Scholar
• Actavis Parma Company. Product monograph: ACT buprenorphine/naloxone [Internet]. Mississauga (ON): Actavis Parma Company; 2017 [ accessed 2017 Mar 7; cited 2017 Mar 26]. https://pdf.hres.ca/dpd_pm/00038368.PDF.
   Google Scholar
• Reckitt Benckiser Pharmaceuticals Inc. NDA 22-410: SUBOXONE® (buprenorphine and naloxone) sublingual film CIII, Buprenorphine (opioid partial agonist-antagonist), -Naloxone (opioid antagonist) [Internet]. Richmond (VA): Reckitt Benckiser Pharmaceuticals Inc; 2014 [ accessed 2014 Apr; cited 2017 Mar 26]. https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm227949.pdf.
   Google Scholar
• U.S. Government Publishing Office. Certification of Opioid Treatment Programs, 42 Code of Federal Regulations (CFR) 8 [Internet]. Washington (DC): U.S. Government Publishing Office; 2017 [ accessed 2017 Sep 26; cited 2017 Sep 27]. https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=3&SID=7282616ac574225f795d5849935efc45&ty=HTML&h=L&n=pt42.1.8&r=PART.
   Google Scholar
• Feder KA, Krawczyk N, Saloner B. Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder. J Adolesc Health. 2017;60(6):747–50. doi:10.1016/j.jadohealth.2016.12.023.
   PubMed Web of Science ®Google Scholar
• Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, Trivedi M, Weiss R, Potter J, Poole SA, et al. Predictors of abstinence: national Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Accad Child Adolesc Psychiatry. 2011;50(11):1120–28. doi:10.1016/j.jaac.2011.07.010.
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. Jama. 2008;300(17):2003–11. doi:10.1001/jama.2008.574.
   PubMed Web of Science ®Google Scholar
• Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010;105(9):1669–76. doi:10.1111/add.2010.105.issue-9.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Tait RJ. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in ‘high-risk’ adolescent heroin users. Addict Biol. 2003;8(3):337–42. doi:10.1080/13556210310001602257.
   PubMed Web of Science ®Google Scholar
• Pecorino A, Fishman M, Ma M, Piralishvili G, Woody GE. Pharmacologically assisted treatment of opioid-dependent youth. Pediatric Drugs. 2013;15(6):449–58. doi:10.1007/s40272-013-0041-5.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Bellisario C, Davoli M. Maintenance treatments for opiate-dependent adolescents. Cochrane Database Syst Rev. 2014;(6):CD007210.
   PubMed Web of Science ®Google Scholar
• Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014;47(3):202–12. doi:10.1016/j.jsat.2014.04.006.
   PubMed Web of Science ®Google Scholar
• Lobmaier P, Kornør H, N K, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD006140.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–46. doi:10.1001/archgenpsychiatry.2011.121.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2016;174(8):738–747.
   PubMed Web of Science ®Google Scholar